TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: PPAR-γ coactivator 1 alpha (PGC-1α) Levels change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Glucose change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HF inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HF cardiometabolic markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood Oxygenation Level Dependent measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic Balance performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adherence to biotherapies
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: CPET/6 minute walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DEXA/muscle MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline amygdalar activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Useful Field of View Composite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of DPR infusion without stopping criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average pain intensity during the last 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: radiographical bone gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: radiographical bone change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Duration of antibiotics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: AO Spine Injury Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients collecting CD34+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Test of Sensory Functions in Infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Electric Impedance Tomography parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of adequate Liver Biopsy specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliable portal pressure gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High contrast visual acuity (logMAR) at 6m
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High contrast visual acuity (logMAR) at 40cm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial count reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuation of Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Grade 3 or Higher TEAEs Based on NCI-CTCAE
Endpoint domain: Adverse events/effects
Primary endpoint: Pain as assessed by the visual analog scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients without prenatal care who received full treatment for syphilis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of patients with no documented syphilis test who received full treatment for syphilis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Perception of effort
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Rate of ctDNA Detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cognitive dysfunction symptom cluster
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in autonomic dysfunction symptom cluster
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in exercise intolerance symptom cluster
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in GAD-7 (Anxiety)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in PHQ-9 (Depression)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Diabetic Foot Self-Care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recruitment yield of participants contacted
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Recruitment yield of participants consented
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Recruitment yield number of participants enrolled
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Session Attendance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Post-operative retinal detachment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Maximal Hand grip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in body weight (kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of total weight loss (%PPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Accumulation of mutations in reproductive tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Score of technical clinical performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score of Non-Technical clinical performance
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Change in Health Related Quality Of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Photogrammetry for Craniocervical angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seated home measured systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Level of phosphorylated PDC protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assess safety changes in electrocardiogram (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy: Objective response rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Rankin Scale at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Modified Rankin Scale at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Maximum tolerated/recommended phase 2 dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evolution of resistance to care
Endpoint domain: Adverse events/effects
Primary endpoint: Volume of enteral feed consumed per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: pp65 T-cell Immune Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Active knee extension test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Goniometer test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of Treatment-Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in negative psychotic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in functioning
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Bone-to-Implant Contact (BIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: complete primary intention healing of the wound dehiscence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Need for sedation during transforaminal epidural injections
Endpoint domain: Adverse events/effects
Primary endpoint: Number of genomic aberrations detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motivation Visual Analog Scale (MVAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Satisfaction Visual Analog Scale (SVAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intrinsic motivation inventory (IMI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anterior teeth alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Interstitial Lung Disease (ILD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Overall Response rate (ORR) per RECIST 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety of Ferric Citrate
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of Ferric Citrate
Endpoint domain: Adverse events/effects
Primary endpoint: Change in coping self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in internalized stigma
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in attitudes toward treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in positive psychosis symptom frequency and distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events (AEs) and laboratory abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of KYV-101 via Myasthenia Gravis Activities of Daily Living (MG-ADL) total score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Functional mobility score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise self-efficacy score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean change in Body Mass Index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Modified Melasma Area and Severity Index (mMASI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Erythema Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of participants with new neurological toxicity (Grade 3 or higher)
Endpoint domain: Adverse events/effects
Primary endpoint: Sensorimotor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular autonomic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of Recovery as measured by the QoR-15F questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Bulk-related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance between EndoSign and upper endoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Ann Arbor staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Schirmer's test (SLT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tear film breakup time (TBUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular Surface Disease Index, OSDI
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mood awareness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-Efficacy Scale for Diabetes Management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Chronic kidney disease frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 1-year PEG feeding tube dependence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients on acalabrutinib therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Ability to mobilise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of positive ctDNA result during surveillance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of positive ctDNA result at first test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of Knee Functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of Knee Joint Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Benzodiazepine administration rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes in emotional cognition
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Resting state oscillations measured with EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Visual analogue score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Difference in resting state IRM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EORTC-QLQ-30 Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Muscle Tissue Oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended phase 2 dose (RP2D) of TBI-2001
Endpoint domain: Adverse events/effects
Primary endpoint: Placebo and nocebo effect on pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Placebo and nocebo effect on attention abilities
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Portion of patients with response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue and serum levels of NLRP1, NLRP3 inflammasomes and Interleukin (IL)-18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Disability measured with SFN-RODS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Health related quality of life measured with SF-12
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Soluble suppression of tumourigenicity 2 (sST2, ng/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Physician Satisfaction With Visits With Lupus Patients
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Difference in Perceived Quality of Visit
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Acceptability of SLE@Duke
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Status of frailty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low-value initial diagnostic imaging
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of participants with an LOAC event
Endpoint domain: Adverse events/effects
Primary endpoint: COVID-19 vaccine effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COVID-19 PCR confirmation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of the BioBlock®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak force of hip abduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average force of hip abduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach peak force of hip abduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: detection of spontaneous inspiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Controlled attenuation parameter (CAP) value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Constant score (Shoulder function score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive predictive symptoms for SIBO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Functional management
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Inter Recti Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lumbopelvic Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Secretion Self-Rating Analog Scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Protoporphyrin IX levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in McGill pain Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Change in Brief Pain Inventory
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Change in Tampa Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Change in Patient global impression of change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: clinical characteristics of COVID-19 associated encephalitis/encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: biomarkers and risk factors of MIS-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in masticatory performance at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in masticatory performance at 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cognitive PCS score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in objective cognitive control accuracy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Usability of the Myosuit
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety of the Myosuit
Endpoint domain: Adverse events/effects
Primary endpoint: Figure of Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Paired-pulse ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Tumor size and extent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diagnostic quality of Cerebral Blood Volume perfusion map
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dubowitz Neurological Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Preterm Oral Feeding Readiness Assessment Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Scores on the Early Literacy Assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion with controlled blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in signs of AA activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in signs of AA inactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in signs of capillary repopulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Aberrant Behavior Checklist, Community
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Blood Glucose Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Shoulder Pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Shoulder ROMs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Shoulder Functionality
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline in reproductive autonomy
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Independent Living Skills Survey
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: number of perinatal, neonatal and in-hospital deaths
Endpoint domain: Mortality/survival
Primary endpoint: days until delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Incidence of Flare Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Fugl-Meyer Assessment scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Index of Erectile Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neural respiratory drive
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient reported breathlessness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prescriptions for HCV treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention